These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536 [TBL] [Abstract][Full Text] [Related]
4. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100 [TBL] [Abstract][Full Text] [Related]
5. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Thompson PA; O'Brien SM; Wierda WG; Ferrajoli A; Stingo F; Smith SC; Burger JA; Estrov Z; Jain N; Kantarjian HM; Keating MJ Cancer; 2015 Oct; 121(20):3612-21. PubMed ID: 26193999 [TBL] [Abstract][Full Text] [Related]
6. [Current diagnosis and treatment of chronic lymphocytic leukaemia]. Cramer P; von Tresckow J; Eichhorst B; Hallek M Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549 [TBL] [Abstract][Full Text] [Related]
7. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718 [TBL] [Abstract][Full Text] [Related]
8. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543 [No Abstract] [Full Text] [Related]
9. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia. İskender G; İskender D; Ertek M Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674 [No Abstract] [Full Text] [Related]
10. Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib. Krečak I; Čengić M; Skorić I; Nakić M; Gverić-Krečak V Ann Hematol; 2021 Nov; 100(11):2861-2862. PubMed ID: 34109444 [No Abstract] [Full Text] [Related]
11. Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib. Martín-Moro F; García-Cosío M; Marquet-Palomanes J; López-Gutiérrez M; Pian-Arias H; López-Jiménez FJ Ann Hematol; 2022 Jan; 101(1):213-215. PubMed ID: 33423076 [No Abstract] [Full Text] [Related]
13. Ibrutinib for treatment of chronic lymphocytic leukemia. Vela CM; McBride A; Jaglowski SM; Andritsos LA Am J Health Syst Pharm; 2016 Mar; 73(6):367-75. PubMed ID: 26953281 [TBL] [Abstract][Full Text] [Related]
14. IBRUTINIB FOR CONTROL OF CHOROIDAL AND ORBITAL METASTASIS FROM CHRONIC LYMPHOCYTIC LEUKEMIA. Sieburth RM; Weaver CD; Kirzhner M; Shildkrot Y Retin Cases Brief Rep; 2023 Mar; 17(2):120-122. PubMed ID: 33411467 [TBL] [Abstract][Full Text] [Related]